ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2362

Evaluation of Disease Activity Using FDG PET-CT in Patients with Large Vessel Vasculitis

Giulia Pazzola1, Luca Magnani1, Luigi Boiardi1, Nicolo Pipitone1, Annibale Versari2, Debora Formisano3, Olga Addimanda1, Riccardo Meliconi4, Lia Pulsatelli5, Gianluigi Bajocchi1, Pierluigi Macchioni1, Maria Grazia Catanoso1, Niccolò Possemato1, Ilaria Padovano1, Alberto Lo Gullo1 and Carlo Salvarani6, 1Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 2Nuclear Medicine, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 3Scientific Directorate, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 4Rheumatology Service and Laboratory of Immuno Rheumatology, Istituto Ortopedico Rizzoli, University of Bologna, Bologna, Italy, 5Laboratory of Immuno Rheumatology,, Istituto Ortopedico Rizzoli, Bologna, Italy, 6Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Diagnostic imaging and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computerized tomography (CT) [PET/CT] has been proposed as a useful tool to diagnose and monitor activity of large vessel vasculitis (LVV), but its precise role remains debated. The objective of this study was to determine the value of PET-CT in the assessment of disease activity in LVV.  To this end, PET/CT findings were correlated with clinical indices including ITAS (Indian Takayasu activity score) and Kerr/National Institute of Health, serum acute-phase reactants (ESR, CRP) levels as well as interleukin-6 (IL-6) and the soluble IL-6 receptor (sIL-6R).

Methods: 78 patients with LVV (giant cell arteritis, Takayasu arteritis or idiopatic aortitis) underwent a total of 204 PET/CT scans. PET/CT scans were reviewed by a nuclear medicine physician without knowledge of clinical information. Vascular uptake was graded using a 4-point semiquantitative scale where grade 0=no uptake, grade 1=less than liver uptake, grade 2=similar to liver uptake, grade 3=higher than liver uptake. Visual analysis was performed on 14 vessel segments. PET/CT scans were considered negative if vascular FDG uptake was grade 0-1, moderately positive if vascular uptake was grade 2, and markedly positive if vascular uptake was grade 3 in at least one vessel. ITAS, Kerr/NIH scores, ESR, CRP, IL-6 and sIL-6R values were obtained within 20 days of PET/CT scans.

Results: 43% of 204 PET-CT were negative, 31% were moderately positive, and 26% were markedly positive. We found a significant  association between the intensity of the uptake and both ESR and CRP levels. Significantly higher ESR values were observed in the patients with markedly positive PET/CT (49.4 + 36.5 mm/1st h) compared with those with moderately positive (27+ 21 mm/1st h, p = 0.0001) and inactive scans ( 22.7 + 15.9 mm/1st h, p=0.0001), respectively. CRP levels were  0.8+1.0 mg/dL in patients with inactive scans,  1.3+ 2.2 mg/dL  in patients with moderately positive (p=0.001) and 3.0 + 3.6  in patients with markedly positive scans (p = 0.0001).  Significantly higher levels of IL-6 were measures  in patients with markedly positive scans (10.0 + 8.9 pg/ml) compared to those with inactive scans (8.1+18.5 pg/ml, p=0.013). No association was found between sIL-6R levels and intensity of vascular FDG uptake. However, there was a significant association between the intensity of vascular FDG uptake and both ITAS and Kerr/NIH scores. 

Patients with markedly positive scans had more frequently (50%) active vasculitis according to the ITAS compared with those with moderately active (31.7%) and inactive scans (28.1%) (p=0.003). Likewise, vasculitis was judged to be active according to the Kerr/NIH index in 50% of patients with markedly positive scans, 22% of those with moderately positive scans, and 14.6% with inactive scans (p=0.0001). 

Conclusion: Our findings show a strong association between vascular FDG uptake and clinical activity and traditional inflammatory markers. A weaker association was found between vascular FDG uptake and IL-6 levels.  These data suggest that PET/CT may be a useful tool for evaluating  disease activity in patients with  LVV.


Disclosure:

G. Pazzola,
None;

L. Magnani,
None;

L. Boiardi,
None;

N. Pipitone,
None;

A. Versari,
None;

D. Formisano,
None;

O. Addimanda,
None;

R. Meliconi,
None;

L. Pulsatelli,
None;

G. Bajocchi,
None;

P. Macchioni,
None;

M. G. Catanoso,
None;

N. Possemato,
None;

I. Padovano,
None;

A. Lo Gullo,
None;

C. Salvarani,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-disease-activity-using-fdg-pet-ct-in-patients-with-large-vessel-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology